
LifeMD (LFMD) Stock Forecast & Price Target
LifeMD (LFMD) Analyst Ratings
Bulls say
LifeMD is forecasting increases in revenue and subscribers in the upcoming quarters, driven by a strong demand for their telehealth services. The recent addition of Foundayo and partnership with LillyDirect will expand their offering of branded GLP-1 therapies and potentially drive further growth. While lower guidance for 2026 may cause concern, the company remains confident in their investments and potential for future profitability. Risks include competition and potential challenges with their technology and data sources, while potential upside could come from favorable outcomes in regulatory inquiries and international market performance.
Bears say
LifeMD is facing significant pressure in the second quarter of 2026, with high cost-per-acquisition and increased competition for its weight loss offerings impacting earnings. Despite recent improvements in both CACs and branded GLP-1 pricing, the company's growth in new weight loss members remains relatively low. In addition, risks such as cybersecurity threats and the need to retain key employees may impact the company's ability to sustain its current growth rates. Despite potential growth in other categories such as Women's Health, the company's young, high-growth nature and reliance on third-party partnerships make it a risky investment.
This aggregate rating is based on analysts' research of LifeMD and is not a guaranteed prediction by Public.com or investment advice.
LifeMD (LFMD) Analyst Forecast & Price Prediction
Start investing in LifeMD (LFMD)
Order type
Buy in
Order amount
Est. shares
0 shares